Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Semaglutide — the active ingredient in Ozempic and Wegovy — may do more than manage diabetes and weight. A large real-world UK study found it was associated with a 38% reduction in asthma attacks and a 21% drop in COPD flare-ups. Researchers say the respiratory benefits appear to go beyond weight loss or blood sugar control alone, though clinical trials are still needed.
Semaglutide, the blockbuster drug behind Ozempic and Wegovy, may have a surprising bonus: better lung health. A large real-world study presented at the European Respiratory Society Congress in Barcelona found that patients with asthma or COPD who took semaglutide for type 2 diabetes had significantly fewer respiratory flare-ups compared to those on sulfonylureas — a different class of diabetes medication.
What makes the findings particularly intriguing is that the respiratory benefits held up regardless of how much weight patients lost or how well their blood sugar was controlled. That suggests semaglutide may have direct anti-inflammatory effects in the lungs, not just indirect benefits from metabolic improvements. Other GLP-1 drugs like exenatide and dulaglutide also showed reductions, but semaglutide led the pack.
By the Numbers:
Why it matters: Asthma and COPD affect hundreds of millions globally, and many patients also live with obesity or type 2 diabetes. If clinical trials confirm these findings, semaglutide could become part of a broader, more personalized treatment strategy for respiratory disease — a significant shift in how metabolic and lung health are managed together.
